Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Erdreich-Epstein, AnatSingh, Alok RJoshi, ShwetaVega, Francisco MGuo, PinzhengXu, JingyingGroshen, SusanYe, WeiMillard, MelissaCampan, MihaelaMorales, GuillermoGarlich, Joseph RLaird, Peter WSeeger, Robert CShimada, HiroyukiDurden, Donald L2025-01-072025-01-072016-11-18https://hdl.handle.net/10668/25125Neuroblastoma (NB) is the most common extracranial solid tumor in children. Our previous studies showed that the angiogenic integrin αvβ3 was increased in high-risk metastatic (stage 4) NB compared with localized neuroblastomas. Herein, we show that integrin αvβ3 was expressed on 68% of microvessels in MYCN-amplified stage 3 neuroblastomas, but only on 34% (means) in MYCN-non-amplified tumors (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/BRD4PI3-kinase inhibitorsangiogenesisintegrin αvβ3neuroblastomaAssociation of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.research article28881723open access10.18632/oncotarget.133861949-2553PMC5581022http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=13386&path%5B%5D=42480https://pmc.ncbi.nlm.nih.gov/articles/PMC5581022/pdf